Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays

Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals (PHAT) to Overweight from Equal Weight with a price target of $18, up from $16. The company’s Q1 trends are “lighter,” but the shares offer an attractive entry point ahead of the expected volume and revenue ramp for the remainder of the year, the analyst tells investors in a research note. The firm believes weekly prescriptions data could be a positive catalyst for Phathom shares. The stock’s setup is positive with consensus revenue expectations at the midpoint of the company’s guidance, contends Barclays.